Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2025-12-24 @ 4:56 PM
NCT ID:
NCT06338150
Eligibility Criteria:
Inclusion Criteria:
* Patients must be 18 years of age at the time of registration.
* Participant must have an established diagnosis of relapsed Multiple Myeloma based on IMWG criteria, be willing to participate, and able to consent
* Participant must have a treating physician who agrees to participate in the study
* Participant will be undergoing a bone marrow biopsy or tumor biopsy as part of their standard of care.
* Patients must be willing to participate in this study and able to sign informed consent.
* Participants are not participating in any interventional clinical trial using systemic therapy directed towards control of MM.
Exclusion Criteria
* Known diagnosis of AL amyloidosis, Waldenstrom Macroglobulinemia, POEMS, or Castleman´s disease.
* Diagnosis of cancer other than myeloma or skin cancer (squamous cell or basal cell) that is ongoing or treated within the last 2 years.
* Tumor sample inadequate or unavailable for analysis (e.g., due to insufficient number of tumor cells).
* Patient will not be receiving systemic MM-directed chemotherapy/immunotherapy in the following 2 months from the time tumor biopsy is performed.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06338150
Study Brief:
Protocol Section:
NCT06338150